Horizon Presents New P-IV Trial Results of Tepezza (teprotumumab-trbw) for the Treatment of Thyroid Eye Disease at ENDO 2023
Shots:
- The P-IV trial evaluating Tepezza vs PBO in adults aged 2-10yrs. with chronic TED & low CAS. The results showed improved visual functioning as measured by GO-QOL, an improvement from baseline for visual functioning (8.73 vs 2.41) @24wk. in the pre-specified analysis of the ITT population
- Change from baseline for appearance (10.03 vs 7.19), improvement in appearance (10.03 vs 7.19) @24wk. per the pre-specified primary analysis (ITT). As previously reported, the trial met its primary & secondary efficacy EPs i.e., reduction in proptosis from baseline (2.41 vs 0.92mm) in the pre-specified primary analysis (ITT) while (2.44 vs 0.69mm) in the pre-specified per-protocol analysis @24wk.
- In ITT & per protocol, improvement in proptosis responder rate (62% vs 25%) & (63% vs 7%) with no new safety signals
Ref: Businesswire | Image: Horizon Therapeutics
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
